Molecular Partners (NASDAQ:MOLN) & Polyrizon (NASDAQ:PLRZ) Financial Review

Polyrizon (NASDAQ:PLRZ) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Polyrizon and Molecular Partners, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1	0	0	0	1.00
Molecular Partners	1	1	2	0	2.25

Molecular Partners has a consensus price target of $8.38, suggesting a potential upside of 99.40%. Given Molecular Partners’ stronger consensus rating and higher probable upside, analysts plainly believe Molecular Partners is more favorable than Polyrizon.

Profitability

This table compares Polyrizon and Molecular Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Molecular Partners	N/A	-60.62%	-51.84%

Volatility and Risk

Polyrizon has a beta of -4.6, suggesting that its stock price is 560% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Valuation and Earnings

This table compares Polyrizon and Molecular Partners”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34 million	N/A	N/A
Molecular Partners	$5.65 million	30.02	-$74.41 million	($1.99)	-2.11

Polyrizon has higher earnings, but lower revenue than Molecular Partners.

Institutional and Insider Ownership

26.6% of Molecular Partners shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Molecular Partners beats Polyrizon on 7 of the 10 factors compared between the two stocks.

About Polyrizon

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.